Search Result

Results for "

cirrhosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (3) Adrenergic Receptor (1) Amino Acid Derivatives (1) Aminopeptidase (1) Amyloid-β (1) Anion Exchangers (1) Apical Sodium-Dependent Bile Acid Transporter (4) Apoptosis (1) Arginase (1) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) COX (2) Cytochrome P450 (1) Drug Derivative (1) Drug Metabolite (3) Endogenous Metabolite (12) Endothelin Receptor (1) Fluorescent Dye (1) FOXO (2) FXR (2) HBV (1) HCV (2) HSV (1) Interleukin Related (2) Isotope-Labeled Compounds (4) Microtubule/Tubulin (2) MMP (1) Monoamine Oxidase (1) NF-κB (3) NKCC (2) NO Synthase (1) PDGFR (1) Peptide-Drug Conjugates (PDCs) (1) PNPLA3 (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) Ser/Thr Protease (1) TGF-beta/Smad (2) TNF Receptor (2) TREM receptor (1) TRP Channel (1) Urea Transporter (3) Vasopressin Receptor (2) VEGFR (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (11) Endocrinology (2) Infection (9) Inflammation/Immunology (16) Metabolic Disease (28) Neurological Disease (4)

By Targets:

17β-HSD (3)

Adrenergic Receptor (1)

Amino Acid Derivatives (1)

Aminopeptidase (1)

Amyloid-β (1)

Anion Exchangers (1)

Apical Sodium-Dependent Bile Acid Transporter (4)

Apoptosis (1)

Arginase (1)

Autophagy (1)

Bacterial (1)

Biochemical Assay Reagents (1)

Carbonic Anhydrase (1)

COX (2)

Cytochrome P450 (1)

Drug Derivative (1)

Drug Metabolite (3)

Endogenous Metabolite (12)

Endothelin Receptor (1)

Fluorescent Dye (1)

FOXO (2)

FXR (2)

HBV (1)

HCV (2)

HSV (1)

Interleukin Related (2)

Isotope-Labeled Compounds (4)

Microtubule/Tubulin (2)

MMP (1)

Monoamine Oxidase (1)

NF-κB (3)

NKCC (2)

NO Synthase (1)

PDGFR (1)

Peptide-Drug Conjugates (PDCs) (1)

PNPLA3 (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (9)

Ser/Thr Protease (1)

TGF-beta/Smad (2)

TNF Receptor (2)

TREM receptor (1)

TRP Channel (1)

Urea Transporter (3)

Vasopressin Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (6)

Cardiovascular Disease (11)

Endocrinology (2)

Infection (9)

Inflammation/Immunology (16)

Metabolic Disease (28)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1788

Taurocholic acid Maximum Cited Publications 31 Publications Verification N-Choloyltaurine	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 31 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	VEGFR Endogenous Metabolite	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-P3465

Bulevirtide 5+ Cited Publications Myrcludex B	HBV	Infection
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .

HY-109120

Odevixibat 4 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-122141

Glycohyocholic acid GHCA	Endogenous Metabolite	Infection Metabolic Disease
Glycohyocholic acid (GHCA) is a primary conjugated bile acid formed by the conjugation of Hyocholic acid (HY-121238) and Glycine (HY-Y0966). Glycohyocholic acid can be used as a biomarker in the study of hepatitis C-related cirrhosis and diabetes .

HY-B0247

Torsemide 1 Publications Verification Torasemide	NKCC	Cardiovascular Disease Metabolic Disease
Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .

HY-N3021

D-chiro-Inositol	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-A0282

L-Ornithine L-aspartate	Amino Acid Derivatives	Metabolic Disease Inflammation/Immunology
L-Ornithine L-aspartate is a stable salt of two natural nonessential L-amino acids with oral activity: ornithine and aspartic acid. L-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis. L-Ornithine L-aspartate also improves mitochondrial functions .

HY-N2127

Pinostrobin 3 Publications Verification	Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent PCSK9 inhibitor that inhibits the catalytic activity of PCSK9. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .

HY-W042301

Xipamide	Anion Exchangers Carbonic Anhydrase Endothelin Receptor	Cardiovascular Disease
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na ⁺/Cl ^--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl ^-/NaCO₃ ^- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca ²⁺ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .

HY-160719

2-octynoic acid-BSA	Peptide-Drug Conjugates (PDCs)	Inflammation/Immunology
NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). When used in combination with Complete Freund's Adjuvant (HY-153808), NHS-activated 2-octynoic acid-BSA stimulates the body's immune system, which recognizes it as a foreign antigen and triggers an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, causing bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for use in primary biliary cholangitis research .

HY-163959

PF-07853578	PNPLA3	Metabolic Disease Cancer
PF-07853578 is an orally active PNPLA3 modulator. PF-07853578 significantly reduces human PNPLA3-I148M protein levels and effectively decreases hepatic triglyceride content by reducing this mutant protein. PNPLA3 degrader-1 can be used in the research of liver cirrhosis and hepatocellular carcinoma .

HY-P5535

Invopressin OCE-205	Vasopressin Receptor	Inflammation/Immunology
Invopressin (Compound 42) is a vasopressin V1A receptor partial agonist (EC₅₀: 1.0 nM). Invopressin can be used for research of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites .

HY-W016798

(S)-2-acetamido-4-amino-4-oxobutanoic acid	Endogenous Metabolite	Metabolic Disease
(S)-2-acetamido-4-amino-4-oxobutanoic acid is a metabolite. (S)-2-acetamido-4-amino-4-oxobutanoic acid can be used in the research of decompensated liver cirrhosis .

HY-N0545R

Taurocholic acid sodium (Standard) 5+ Cited Publications Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Reference Standards VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-147358

Yimitasvir diphosphate Emitasvir diphosphate; DAG-181 diphosphate	HCV	Infection
Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection .

HY-169004

CBT-295	TGF-beta/Smad Interleukin Related	Neurological Disease Inflammation/Immunology
CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .

HY-B0247S

Torsemide-d7 Torasemide-d₇	Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Torsemide-d₇ is the deuterium labeled Torsemide. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .

HY-B0247R

Torsemide (Standard) 1 Publications Verification Torasemide (Standard)	NKCC Reference Standards	Cardiovascular Disease Metabolic Disease
Torsemide (Standard) is the analytical standard of Torsemide. This product is intended for research and analytical applications. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .

HY-126128

Heliotrine	Biochemical Assay Reagents	Cancer
Heliotrine is a monoester pyrrolizidine alkaloid and is used for obtaining models of hepatitis and cirrhosis of the liver .

HY-18344

Satavaptan SR 121463	Vasopressin Receptor	Metabolic Disease
Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia .

HY-118167

Monoethylglycinexylidide	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Monoethylglycinexylidide is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver ^{[1] ^.}

HY-B1788R

Taurocholic acid (Standard) N-Choloyltaurine (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-147358A

Yimitasvir Emitasvir; DAG-181	HCV	Infection
Yimitasvir (Emitasvir; DAG-181) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir is applicable to research related to HCV infection .

HY-N3021R

D-chiro-Inositol (Standard)	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-118028

Leyk	Drug Derivative	Cardiovascular Disease Inflammation/Immunology
Leyk is an orally active Cysteine derivative. Leyk stimulates bone marrow hematopoiesis. Leyk exerts a significant protective effect against cyclophosphamide-induced leukopenia. Leyk can be used in studies related to thrombocytopenia and leukopenia .

HY-W010270A

Aurothiomalate disodium	TRP Channel NF-κB NO Synthase TREM receptor Arginase	Metabolic Disease Inflammation/Immunology
Aurothiomalate (disodium) is a TRPA1 inhibitor. Aurothiomalate (disodium) inhibits NF-κB activation and iNOS expression. Aurothiomalate (disodium) promotes M2 transformation of macrophages and increases the expression of TREM-2 and arginase-1. Aurothiomalate (disodium) can be used in the study of liver fibrosis/cirrhosis and arthritis .

HY-134221

S-Nitroso-N-acetylcysteine	Adrenergic Receptor Reactive Oxygen Species (ROS)	Cardiovascular Disease
S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis .

HY-W775009

Imidazole salicylate	COX	Inflammation/Immunology
Imidazole salicylate is a nonsteroidal anti-inflammatory drug that can be used to study cirrhosis and ascites .

HY-W775009R

Imidazole salicylate (Standard)	COX Reference Standards	Inflammation/Immunology
Imidazole salicylate (Standard) is the analytical standard of Imidazole salicylate. This product is intended for research and analytical applications. Imidazole salicylate is a nonsteroidal anti-inflammatory drug that can be used to study cirrhosis and ascites .

HY-122141S

Glycohyocholic acid-d4 Glycine hyocholate-d₄	Endogenous Metabolite Isotope-Labeled Compounds	Infection Metabolic Disease
Glycohyocholic acid-d₄ is the deuterium labeled Glycohyocholic acid (HY-122141). Glycohyocholic acid (GHCA) is a primary conjugated bile acid formed by the conjugation of Cholic acid (HY-N0324) and Glycine (HY-Y0966). Glycohyocholic acid can be used in the study of hepatitis C-related cirrhosis and diabetes mellitus .

HY-157650

HSD17B13-IN-20	17β-HSD	Metabolic Disease
HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-157653

HSD17B13-IN-22	17β-HSD	Metabolic Disease
HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-157654

HSD17B13-IN-26	17β-HSD	Metabolic Disease
HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120R

Odevixibat (Standard) A4250 (Standard)	Apical Sodium-Dependent Bile Acid Transporter Reference Standards	Metabolic Disease
Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-148514

CT52923	PDGFR	Cancer
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer .

HY-106894

Lufironil HOE 077	Drug Metabolite	Others
Lufironil (HOE 077) is a prolyl 4-hydroxylase inhibitor. Lufironil is developed for the research of chronic liver diseases including alcoholic hepatitis and liver cirrhosis .

HY-19421

Orazamide	Bacterial	Inflammation/Immunology
Orazamide is an AICA orotate. Orazamide can prevent anti-TB drug-induced liver damage by downregulating the protein expression of HMGB 1 and RAGE in liver tissue and inhibiting the secretion of inflammatory factors. Orazamide can be used in research on hepatitis and liver cirrhosis .

HY-150787

BMS-986339	FXR Cytochrome P450	Metabolic Disease
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .

HY-118167R

Monoethylglycinexylidide (Standard)	Reference Standards Drug Metabolite	Metabolic Disease Inflammation/Immunology
Monoethylglycinexylidide (Standard) is the analytical standard of Monoethylglycinexylidide. This product is intended for research and analytical applications. Monoethylglycinexylidide is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver .

HY-N13208

Stevia Powder	MMP TGF-beta/Smad	Others
Stevia Powder is a natural sweetener with antioxidant activity. Stevia Powder can downregulate pro fibrotic pathways in cirrhotic rats, including reduced hepatic myofibroblasts and decreased expression of matrix metalloproteinases MMP2 and MMP13, upregulate anti fibrotic molecule Smad7, prevent serum necrosis and elevated bile stasis markers, thereby inhibiting the development of liver fibrosis .

HY-109083A

Cilofexor tromethamine GS-9674 tromethamine	Autophagy FXR	Metabolic Disease
Cilofexor tromethamine (GS-9674 tromethamine) is a nonsteroidal farnesene oxide receptor agonist with activity in improving markers of cholestasis and liver injury. Cilofexor tromethamine was shown to be well tolerated in patients without cirrhosis and resulted in significant improvements in liver biochemical parameters and cholestatic markers. Cilofexor tromethamine offers a potential inhibitory option for the management of primary sclerosing cholangitis .

HY-122141R

Glycohyocholic acid (Standard) GHCA (Standard)	Reference Standards Endogenous Metabolite	Infection Metabolic Disease
Glycohyocholic acid (Standard) is the analytical standard of Glycohyocholic acid (HY-122141). This product is intended for use in research and analytical applications. Glycohyocholic acid (GHCA) is a primary conjugated bile acid formed by the conjugation of Cholic acid (HY-N0324) and Glycine (HY-Y0966). Glycohyocholic acid can be used in the study of hepatitis C-related cirrhosis and diabetes mellitus .

HY-W016798R

(S)-2-acetamido-4-amino-4-oxobutanoic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
(S)-2-acetamido-4-amino-4-oxobutanoic acid (Standard) is an analytical standard for (S)-2-acetamido-4-amino-4-oxobutanoic acid (HY-W016798). This product is intended for research and analytical applications. (S)-2-acetamido-4-amino-4-oxobutanoic acid is a metabolite. (S)-2-acetamido-4-amino-4-oxobutanoic acid can be used in the research of decompensated liver cirrhosis.

HY-D3191

L&M-D-MR	Fluorescent Dye Aminopeptidase Monoamine Oxidase	Infection Metabolic Disease
L&M-D-MR is a highly specific fluorescent "AND" logic probe with response moieties for leucine aminopeptidase (LAP) and monoamine oxidase (MAO). The coexistence of both LAP and MAO is required for L&M-D-MR to trigger intramolecular cyclization, release fluorophores and activate fluorescence. In the presence of only a single enzyme, L&M-D-MR generates only an extremely weak signal. L&M-D-MR enables bioimaging in living cells and mouse models, and can effectively distinguish different subtypes of liver diseases via blood samples or test strips. L&M-D-MR is widely used in studies related to liver cirrhosis, hepatitis B and drug-induced liver injury .

HY-P2032

Cyclochlorotine	Endogenous Metabolite	Infection Cancer
Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity .

HY-183637

E822-1968	Urea Transporter	Cardiovascular Disease Metabolic Disease Endocrinology
E822-1968 is an UT-A2 inhibitor with a human IC₅₀ of 0.44 μM. E822-1968 blocks urea transport mediated by UT-A2. E822-1968 can be used for the study of hyponatremia and edema associated with congestive heart failure, nephrotic syndrome, and cirrhosis .

HY-116718

UTA1inh-D1	Urea Transporter	Cardiovascular Disease
UTA1inh-D1 is a selective UT-A1 and UT-B urea transporter inhibitor with IC₅₀ values of 3.8 μM and 15 μM, respectively. UTA1inh-D1 is promising for research of refractory edema, such as congestive heart failure and cirrhosis .

Cat. No.	Product Name

HY-L060

Cytoskeleton Compound Library

2,148 compounds

The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.

MCE designs a unique collection of 2,148 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

HY-L073

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

4,703 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,703 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

HY-L101

Anti-Liver Cancer Compound Library

2,838 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,838 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-D3191

L&M-D-MR

Fluorescent Dyes

L&M-D-MR is a highly specific fluorescent "AND" logic probe with response moieties for leucine aminopeptidase (LAP) and monoamine oxidase (MAO). The coexistence of both LAP and MAO is required for L&M-D-MR to trigger intramolecular cyclization, release fluorophores and activate fluorescence. In the presence of only a single enzyme, L&M-D-MR generates only an extremely weak signal. L&M-D-MR enables bioimaging in living cells and mouse models, and can effectively distinguish different subtypes of liver diseases via blood samples or test strips. L&M-D-MR is widely used in studies related to liver cirrhosis, hepatitis B and drug-induced liver injury .

Cat. No.	Product Name	Target	Research Area

HY-P3465

Bulevirtide 5+ Cited Publications Myrcludex B	HBV	Infection
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .

HY-P5535

Invopressin OCE-205	Vasopressin Receptor	Inflammation/Immunology
Invopressin (Compound 42) is a vasopressin V1A receptor partial agonist (EC₅₀: 1.0 nM). Invopressin can be used for research of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites .

HY-P2032

Cyclochlorotine	Endogenous Metabolite	Infection Cancer
Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1788

Taurocholic acid Maximum Cited Publications 31 Publications Verification N-Choloyltaurine	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 31 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	Structural Classification Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	VEGFR Endogenous Metabolite
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-122141

Glycohyocholic acid GHCA	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycohyocholic acid (GHCA) is a primary conjugated bile acid formed by the conjugation of Hyocholic acid (HY-121238) and Glycine (HY-Y0966). Glycohyocholic acid can be used as a biomarker in the study of hepatitis C-related cirrhosis and diabetes .

HY-N3021

D-chiro-Inositol	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N2127

Pinostrobin 3 Publications Verification	Monophenols Flavonoids other families Classification of Application Fields Flavonones Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related
Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent PCSK9 inhibitor that inhibits the catalytic activity of PCSK9. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .

HY-W016798

(S)-2-acetamido-4-amino-4-oxobutanoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
(S)-2-acetamido-4-amino-4-oxobutanoic acid is a metabolite. (S)-2-acetamido-4-amino-4-oxobutanoic acid can be used in the research of decompensated liver cirrhosis .

HY-N0545R

Taurocholic acid sodium (Standard) 5+ Cited Publications Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Structural Classification Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Reference Standards VEGFR Endogenous Metabolite
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788R

Taurocholic acid (Standard) N-Choloyltaurine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N3021R

D-chiro-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-122141R

Glycohyocholic acid (Standard) GHCA (Standard)	Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
Glycohyocholic acid (Standard) is the analytical standard of Glycohyocholic acid (HY-122141). This product is intended for use in research and analytical applications. Glycohyocholic acid (GHCA) is a primary conjugated bile acid formed by the conjugation of Cholic acid (HY-N0324) and Glycine (HY-Y0966). Glycohyocholic acid can be used in the study of hepatitis C-related cirrhosis and diabetes mellitus .

HY-W016798R

(S)-2-acetamido-4-amino-4-oxobutanoic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
(S)-2-acetamido-4-amino-4-oxobutanoic acid (Standard) is an analytical standard for (S)-2-acetamido-4-amino-4-oxobutanoic acid (HY-W016798). This product is intended for research and analytical applications. (S)-2-acetamido-4-amino-4-oxobutanoic acid is a metabolite. (S)-2-acetamido-4-amino-4-oxobutanoic acid can be used in the research of decompensated liver cirrhosis.

HY-P2032

Cyclochlorotine	Microorganisms Cyclopeptides Source Classification	Endogenous Metabolite
Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity .

Cat. No.	Product Name	Chemical Structure

HY-B0247S

Torsemide-d7
Torsemide-d₇ is the deuterium labeled Torsemide. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .

HY-122141S

Glycohyocholic acid-d4
Glycohyocholic acid-d₄ is the deuterium labeled Glycohyocholic acid (HY-122141). Glycohyocholic acid (GHCA) is a primary conjugated bile acid formed by the conjugation of Cholic acid (HY-N0324) and Glycine (HY-Y0966). Glycohyocholic acid can be used in the study of hepatitis C-related cirrhosis and diabetes mellitus .

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

Host:	Mouse (3)
Reactivity:	Human (2) Mouse (1) Rabbit (1) human (1)
Application:	IHC-P (1) ICC/IF (2) IF-Tissue (1) IP (2) WB (3) ELISA (1)
Isotype:	IgG1 (1)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85448

	Pyruvate Dehydrogenase E2 Antibody (YA5140) DLAT; DLTA; Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; mitochondrial; 70 kDa mitochondrial autoantigen of primary biliary cirrhosis; PBC; Dihydrolipoamide acetyltransferase component of pyruva	WB	Human, Rabbit
	Pyruvate Dehydrogenase E2 Antibody (YA5140) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Pyruvate Dehydrogenase E2.

HY-P89693

	E3BP Antibody (YA9037) DLTA, DLAT, 70 kDa mitochondrial autoantigen of primary biliary cirrhosis, Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex, M2 antigen complex 70 kDa subunit, Pyruvate dehydrogenase complex component E2, PBC, PDC-E2, PDCE2	WB, ICC/IF, IF-Tissue, IHC-P, IP, ELISA	human
	E3BP Antibody (YA9037) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to E3BP.

HY-P85556

	Pyruvate Dehydrogenase E2 Antibody (YA5248) 70 kDa mitochondrial autoantigen of primary biliary cirrhosis; anti DLAT; Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex; Dihydrolipoamide; Dihydrolipoamide S Acetyltransferase; Dihydrolipoamide S-acetyltransferase; E2 component of pyruvate dehydrogenase complex; Dihydrolipoamide S-Acetyltransferase; Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex mitochondrial; DLAT; DLAT; DLTA; E2; E2 component of pyruvate dehydrogenase complex; M2 antigen complex 70 kDa subunit; M2 Antigen Complex 70kD Subunit; mitochondrial; ODP2_HUMAN; PBC; PDC E2; PDC-E2; PDCE2; Pyruvate dehydrogenase complex component E2; Pyruvate dehydrogenase complex E2 subunit; S acetyltransferase component of pyruvate dehydrogenase complex.	WB, ICC/IF, IP	Human, Mouse
	Pyruvate Dehydrogenase E2 Antibody (YA5248) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Pyruvate Dehydrogenase E2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cirrhosis

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products